Cargando…

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol

INTRODUCTION: Pharmaceutical treatment options for patients with type 2 diabetes mellitus (T2DM) have increased to include multiple classes of oral glucose-lowering agents but without accompanying guidance on which of these may most benefit individual patients. Clinicians lack information for treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angwin, Catherine, Jenkinson, Caroline, Jones, Angus, Jennison, Christopher, Henley, William, Farmer, Andrew, Sattar, Naveed, Holman, Rury R, Pearson, Ewan, Shields, Beverley, Hattersley, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754630/ https://www.ncbi.nlm.nih.gov/pubmed/33371044 http://dx.doi.org/10.1136/bmjopen-2020-042784

Ejemplares similares

Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study
por: Eibich, Peter, et al.
Publicado: (2017)

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
por: Kim, Kyuho, et al.
Publicado: (2021)

DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
por: Wong, Carlos K H, et al.
Publicado: (2020)

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
por: Kimura, Tomomi, et al.
Publicado: (2012)

Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes
por: Rodgers, Lauren R, et al.
Publicado: (2017)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
por: Lee, Kyeong Won, et al.
Publicado: (2011)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
por: Kim, Sun Woo
Publicado: (2010)

Midsummer mysteries: Criminal masterminds? Not really…
por: Antonella Del Rosso
Publicado: (2014)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis
por: Brath, Helmut, et al.
Publicado: (2017)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes–Induced Blood–Brain Barrier Leakage and Normalize Capillary Pericyte Coverage
por: Elabi, Osama F., et al.
Publicado: (2023)

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
por: McGovern, Andrew P., et al.
Publicado: (2019)

Selective Phenotyping, Entropy Reduction, and the Mastermind game
por: Gagneur, Julien, et al.
Publicado: (2011)

Felix Berezin: Life and death of the mastermind of supermathematics
por: Shifman, M, et al.
Publicado: (2007)

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
por: Dennis, John M., et al.
Publicado: (2019)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
por: Kang, Yu Mi, et al.
Publicado: (2019)

Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Kay, Stephen, et al.
Publicado: (2017)

Masterminds of programming: conversations with the creators of major programming languages
por: Biancuzzi, Federico, et al.
Publicado: (2009)

Securing Office 365: masterminding MDM and compliance in the cloud
por: Katzer, Matthew
Publicado: (2018)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study
por: Wong, Carlos K. H., et al.
Publicado: (2019)

Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
por: Sharma, Chiranjeev, et al.
Publicado: (2019)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Mastermind-Like 1 Is Ubiquitinated: Functional Consequences for Notch Signaling
por: Farshbaf, Mozhgan, et al.
Publicado: (2015)

Discovery Potent of Thiazolidinedione Derivatives as Antioxidant, α-Amylase Inhibitor, and Antidiabetic Agent
por: Sameeh, Manal Y., et al.
Publicado: (2021)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Design, synthesis, and screening of sulfonylurea-derived NLRP3 inflammasome inhibitors
por: Kulkarni, Amol A., et al.
Publicado: (2019)

Association of Hemoglobin A(1c) Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative
por: Vashisht, Rohit, et al.
Publicado: (2018)

Using the Game of Mastermind to Teach, Practice, and Discuss Scientific Reasoning Skills
por: Strom, Amy R., et al.
Publicado: (2011)

mastermind regulates niche ageing independently of the Notch pathway in the Drosophila ovary
por: Lobo-Pecellín, María, et al.
Publicado: (2019)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ajd56jkn5utbcr9rrajeetol6h